Serum visfatin levels in patients with subclinical and newly diagnosed type 2 diabetes mellitus


çelebi A., Gurler M., ÖĞÜTMEN KOÇ D., Ozdemir A. A., Ekizoglu I., Altay M., ...Daha Fazla

Acta Medica Mediterranea, cilt.33, sa.2, ss.197-202, 2017 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.19193/0393-6384_2017_2_028
  • Dergi Adı: Acta Medica Mediterranea
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.197-202
  • Anahtar Kelimeler: Subclinical diabetes mellitus, Type 2 diabetes mellitus, Visfatin
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Introduction: The present study aimed to compare serum visfatin levels among subjects with subclinical diabetes/pre-diabetes (impaired fasting glucose [IFG] alone and IFG+impaired glucose tolerance [IGT]), subjects with newly diagnosed type 2 diabetes mellitus (DM), and healthy nondiabeticnormoglycemic controls and to evaluate the relation of serum visfatin levels with some metabolic parameters and insulin resistance. Materials and methods: The study was conducted in 80 subjects, of whom 52 (65%) were female and 28 (35%) were male. The subjects were divided into 4 groups as control, IFG, IFG+IGT, and newly diagnosed type 2 DM groups, containing 20 subjects in each. Waist and hip circumferences, age, gender, body mass index, and demographic characteristics were recorded in each group. The levels of fasting plasma glucose, fasting serum insulin, C-peptide, cortisol, glycosylated hemoglobin (HbA1c), total cholesterol, highdensity lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDLC), triglyceride were measured and insulin/C-peptide ratio and the homeostasis model assessment-insulin resistance (HOMA-IR) were calculated and compared among the groups. Results: In line with glucose metabolism disorder, significant increases were observed in the insulin, C-peptide, insulin/C-peptide ratio, HbA1c (%), HOMA-IR values, cardiovascular risk parameters (total cholesterol, LDL-C, VLDL-C, triglyceride), and visfatin levels in the subclinical diabetes and diabetes groups as compared to the control group. Conclusion: Visfatin could be considered among therapeutic agents used in the prevention of diabetes and in the prevention or reduction of its critical complications.